Commentary: An In Silico - In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients

被引：4

作者：

Beer, Ilan ^{[1
]}

机构：

[1] Adicet Bio Inc, Menlo Pk, CA 94025 USA

来源：

FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷

关键词：

peptide splicing; proteasome; KRAS mutation; HLA; mass spectrometry;

D O I：

10.3389/fimmu.2021.523906

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

收藏

页数：3

相关论文

共 1 条

[1] An in silico-in vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients [J].

Mishto, Michele ;

Mansurkhodzhaev, Artem ;

Ying, Ge ;

Bitra, Aruna ;

Cordfunke, Robert A. ;

Henze, Sarah ;

Paul, Debdas ;

Sidney, John ;

Urlaub, Henning ;

Neefjes, Jacques ;

Sette, Alessandro ;

Zajonc, Dirk M. ;

Liepe, Juliane .

FRONTIERS IN IMMUNOLOGY, 2019, 10